• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Evogene Ltd

    2/14/24 8:30:01 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials
    Get the next $EVGN alert in real time by email
    SC 13G 1 evgn-sc13g_123123.htm SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. __)*

     

    Evogene Ltd.

    (Name of Issuer)

     

    Common Stock 

    (Title of Class of Securities)

     

    M4119S104 

    (CUSIP Number)

     

    December 31, 2023 

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☒  Rule 13d-1(b)
    ☐  Rule 13d-1(c)
    ☐  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. M4119S104 13G Page 2 of 9

     

    1. NAMES OF REPORTING PERSONS

    SilverArc Capital Management, LLC
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☐
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER
     
    0
    6. SHARED VOTING POWER
     
    3,100,000
    7. SOLE DISPOSITIVE POWER
     
    0
    8. SHARED DISPOSITIVE POWER
     
    3,100,000
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,100,000
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.1%
    12. TYPE OF REPORTING PERSON (see instructions)

    IA
           

     

     

     

    CUSIP No. M4119S104 13G Page 3 of 9

     

    1. NAMES OF REPORTING PERSONS

    Devesh Gandhi
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ☐
    (b)    ☐
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER
     
    0
    6. SHARED VOTING POWER
     
    3,100,000
    7. SOLE DISPOSITIVE POWER
     
    0
    8. SHARED DISPOSITIVE POWER
     
    3,100,000
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,100,000
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.1%
    12. TYPE OF REPORTING PERSON (see instructions)

    IN
           

     

     

     

    CUSIP No. M4119S104 13G Page 4 of 9

     

    Item 1.

     

    (a)Name of Issuer

     

    Evogene Ltd.

     

    (b)Address of Issuer’s Principal Executive Offices

     

    13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel.

     

    Item 2.

     

    (a)Name of Person Filing

     

    SilverArc Capital Management, LLC (“SilverArc”) and Devesh Gandhi (“Gandhi” and together with SilverArc, the “Reporting Persons”)

     

    (b)Address of the Principal Office or, if none, residence

     

    20 Park Plaza, 4th Floor 

    Boston, MA 02116

     

    (c)Citizenship

     

    SilverArc is a Delaware limited liability company. Gandhi is a citizen of the United States.

     

    (d)Title of Class of Securities

     

    Common Stock

     

    (e)CUSIP Number

     

    M4119S104

     

     

     

     

    CUSIP No. M4119S104 13G Page 5 of 9

     

    Item 3. If this statement is filed pursuant to Sec. 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)☐ Broker or dealer registered under section 15 of the Act (15 U.S.D. 78o):

    (b)☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c)☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

    (d)☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

    (e)☒ An investment adviser in accordance with Sec. 240.13d-1(b)(1)(ii)(E);

    (f)☐ An employee benefit plan or endowment fund in accordance with Sec. 240.13d-1(b)(1)(ii)(F);

    (g)☒ A parent holding company or control person in accordance with Sec. 240.13d-1(b)(1)(ii)(G);

    (h)☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i)☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j)☐ A non-U.S. institution in accordance with Sec. 240.13d-1(b)(1)(ii)(J);

    (k)☐ Group, in accordance with Sec. 240.13d-1(b)(1)(ii)(J). 

     

    Item 4. Ownership

     

    This statement is being filed with respect to an aggregate of 3,100,000 shares of Common Stock, resulting in beneficial ownership of Common Stock as follows:

     

    1.SilverArc

     

    (a)Amount Beneficially owned: 3,100,000

     

    (b)Percent of Class: 6.1%.

     

    (c)Number of shares to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0.

     

    (ii)Shared power to vote or to direct the vote: 3,100,000

     

    (iii)Sole power to dispose or to direct the disposition of: 0.

     

    (iv)Shared power to dispose or to direct the disposition of: 3,100,000

     

    2.Gandhi

     

    (d)Amount Beneficially owned: 3,100,000

     

    (e)Percent of Class: 6.1%.

     

    (f)Number of shares to which the person has:

     

    (v)Sole power to vote or to direct the vote: 0.

     

    (vi)Shared power to vote or to direct the vote: 3,100,000

     

    (vii)Sole power to dispose or to direct the disposition of: 0.

     

     

     

     

    CUSIP No. M4119S104 13G Page 6 of 9

     

    (viii) Shared power to dispose or to direct the disposition of: 3,100,000.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    ☐As of the date of this Report, the aggregate beneficial ownership of the Reporting Persons had been reduced to below five percent (5%).

     

    Item 6.Ownership of More than Five Percent on Behalf of another Person.

     

    SilverArc, an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is deemed to be the beneficial owner of 3,100,000 shares, or 6.1% of the Common Stock believed to be outstanding, as a result of acting as investment adviser to various clients. Gandhi is the Sole Member of SilverArc and as such is deemed to be the beneficial owner of 3,100,000 shares, or 6.1% of the Common Stock believed to be outstanding.  Clients of SilverArc have the right to receive and the ultimate power to direct the receipt of dividends from, or the proceeds of the sale of, such securities. SilverArc Capital Alpha Fund I, L.P., a Delaware limited partnership for which SilverArc acts as an investment adviser, may be deemed to beneficially own 109,587 of these 3,100,00 shares, which equates to 0.2% of the Common Stock believed to be outstanding. SilverArc Capital Alpha Fund II, L.P., a Delaware limited partnership for which SilverArc acts as an investment adviser, may be deemed to beneficially own 1,946,922 of these 3,100,000 shares, which equates to 3.8% of the Common Stock believed to be outstanding. Squarepoint Diversified Partners Fund Limited, a Cayman Island exempted company for which SilverArc acts as investment adviser, may be deemed to beneficially own 695,935 of these 3,100,000 shares, which equates to 1.4% of the Common Stock believed to be outstanding. Atom Master Fund L.P., a Cayman Islands exempted limited partnership for which SilverArc acts as investment adviser, may be deemed to beneficially own 347,556 of these 3,100,000 shares, which equates to 0.7% of the Common Stock believed to be outstanding.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not Applicable

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not Applicable

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable

     

     

     

    CUSIP No. M4119S104 13G Page 7 of 9

     

    Item 10.Certification

     

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Exhibits.

     

    Exhibit A Joint Filing Agreement by and between the Reporting Persons dated February 14, 2024.

     

     

     

     

    CUSIP No. M4119S104 13G Page 8 of 9

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 

     

      February 14, 2024
      Date

     

    /s/ Devesh S. Gandhi 

     
    Devesh S. Gandhi, as Sole Member of SilverArc Capital Management, LLC  

     

    /s/ Devesh S. Gandhi 

     
    Devesh S. Gandhi  

     

     

     

     

    CUSIP No. M4119S104 13G Page 9 of 9

     

    EXHIBIT INDEX 

    Ex.  
       
    A Joint Filing Agreement

     

     

    Get the next $EVGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVGN

    DatePrice TargetRatingAnalyst
    11/24/2021$8.00 → $7.00Outperform
    RBC Capital
    10/8/2021$7.00Buy
    ROTH Capital
    8/23/2021$8.00Outperform
    RBC Capital
    7/29/2021$10.00Buy
    Aegis Capital
    More analyst ratings

    $EVGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital reiterated coverage on EverGen Infrastructure with a new price target

      RBC Capital reiterated coverage of EverGen Infrastructure with a rating of Outperform and set a new price target of $7.00 from $8.00 previously

      11/24/21 7:31:39 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • ROTH Capital initiated coverage on Evogene with a new price target

      ROTH Capital initiated coverage of Evogene with a rating of Buy and set a new price target of $7.00

      10/8/21 8:30:09 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • RBC Capital initiated coverage on EverGen Infrastructure Corp. with a new price target

      RBC Capital initiated coverage of EverGen Infrastructure Corp. with a rating of Outperform and set a new price target of $8.00

      8/23/21 11:09:14 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials

    $EVGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025

      Mr. Nir Nirmodi is Replacing Ms. Sarit Firon, who will Continue Serving as a Member of the Board REHOVOT, Israel, March 6, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, today announced the appointment of Mr. Nir Nimrodi as the new Chairperson of the Board, succeeding Ms. Sarit Firon, who has held the position since August 2021. Ms. Firon will continue to serve as a member of the Board. As Evogene progresses toward key milestones across its subsidiaries and programs, Mr. Nimrodi's extensive experience in scaling life sciences businesses and driving growth make

      3/6/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • Casterra Appoints New CEO and Expands Team to Drive Growth and Innovation

      Mr. Yoash Zohar, a seasoned ag executive, is joining Casterra as CEO to lead the company's significant operational expansion REHOVOT, Israel, Dec. 19, 2023 /PRNewswire/ -- Casterra Ag Ltd., a subsidiary of Evogene Ltd. ("Evogene") (NASDAQ:EVGN) (TASE: EVGN) and an integrated castor cultivation solution company for the bio-based industries (e.g. biofuels, biopolymers), today announced the appointment of Mr. Yoash Zohar as new CEO, as of January 1, 2024, to lead the company's expansion efforts. Considering Casterra's rapid growth and its continued prospects for development, this nomination aims to strengthen its leadership and positioning in the industry. Casterra entered a new phase in its l

      12/19/23 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • AgPlenus Appoints Dr. Adrian Percy to Its Board of Directors

      REHOVOT, Israel, July 12, 2023 /PRNewswire/ -- AgPlenus Ltd., an innovative company designing novel and safe crop protection products allowing food security for a rapidly growing world population, and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), is pleased to announce the appointment of Dr. Adrian Percy to its board of directors. Dr. Percy, who also serves as a member of Evogene Ltd.'s board of directors since March 2019, brings a wealth of expertise and a deep commitment to advancing environmentally friendly agricultural technologies. With over 25 years of experience in the agricultural industry, Dr. Adrian Percy strongly advocates for environmentally friendly agricultural and f

      7/12/23 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials

    $EVGN
    Financials

    Live finance-specific insights

    See more
    • Evogene Schedules First Quarter 2025 Financial Results Release

      Zoom conference call scheduled for May 21, 2025, 9:00 AM ET REHOVOT, Israel, May 8, 2025 /PRNewswire/ -- May 8, 2025 - Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Wednesday, May 21, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://www.veidan-conferenceing.com/evogene The entire conference will be available online on the company's website a fe

      5/8/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

      Conference call and webcast: today, March 6, 2025, 9:00 am ET Financial Highlights: In the year 2024, total revenues reached approximately $8.5 million compared to approximately $5.6 million in the year 2023. The increase in revenues is mainly due to increase in AgPlenus' revenues from its collaboration with Bayer and an increase in Casterra's seed sales.In Q4 2024, total revenues reached approximately $1.6 million compared to approximately $0.6 million in Q4 2023. The increase in revenues is mainly due to the increase in Casterra's seed sales.Revenues in Q4 2024 were originally expected to be higher, however, there was a change in delivery schedule of Casterra's seeds from 2024 to 2025. In

      3/6/25 7:15:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • Evogene Schedules Fourth Quarter 2024 Financial Results Release

      Zoom conference call scheduled for March 6, 2025, 9:00 AM ET REHOVOT, Israel, Feb. 20, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the fourth quarter of 2024, on Thursday, March 6, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://us06web.zoom.us/webinar/register/WN_1cToyoipTfW8X0xtgEqPfw The entire conference will be available online on the company's

      2/20/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials

    $EVGN
    SEC Filings

    See more
    • SEC Form 6-K filed by Evogene Ltd

      6-K - Evogene Ltd. (0001574565) (Filer)

      4/21/25 7:00:10 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • SEC Form EFFECT filed by Evogene Ltd

      EFFECT - Evogene Ltd. (0001574565) (Filer)

      4/3/25 12:15:13 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • SEC Form POS AM filed by Evogene Ltd

      POS AM - Evogene Ltd. (0001574565) (Filer)

      3/28/25 6:09:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials

    $EVGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $EVGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Evogene Schedules First Quarter 2025 Financial Results Release

      Zoom conference call scheduled for May 21, 2025, 9:00 AM ET REHOVOT, Israel, May 8, 2025 /PRNewswire/ -- May 8, 2025 - Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Wednesday, May 21, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://www.veidan-conferenceing.com/evogene The entire conference will be available online on the company's website a fe

      5/8/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio

      Lavie Bio improves agriculture productivity and sustainability through microbiome-based ag-biological products REHOVOT, Israel, April 21, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN) a leading computational biology company focused on revolutionizing life-science-based product discovery and development, today announced the signing of a definitive agreement under which ICL, will acquire the majority of activity of Evogene's subsidiary, Lavie Bio Ltd. As part of the agreement, ICL will also acquire Evogene's MicroBoost AI for AG platform.     The transaction is expected to close during the second quarter of 2025, subject to the fulfillment of customary closing conditions. Lavie

      4/21/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

      Conference call and webcast: today, March 6, 2025, 9:00 am ET Financial Highlights: In the year 2024, total revenues reached approximately $8.5 million compared to approximately $5.6 million in the year 2023. The increase in revenues is mainly due to increase in AgPlenus' revenues from its collaboration with Bayer and an increase in Casterra's seed sales.In Q4 2024, total revenues reached approximately $1.6 million compared to approximately $0.6 million in Q4 2023. The increase in revenues is mainly due to the increase in Casterra's seed sales.Revenues in Q4 2024 were originally expected to be higher, however, there was a change in delivery schedule of Casterra's seeds from 2024 to 2025. In

      3/6/25 7:15:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Evogene Ltd

      SC 13G/A - Evogene Ltd. (0001574565) (Subject)

      10/15/24 6:52:26 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • SEC Form SC 13G filed by Evogene Ltd

      SC 13G - Evogene Ltd. (0001574565) (Subject)

      2/14/24 8:30:01 PM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • SEC Form SC 13G/A filed by Evogene Ltd (Amendment)

      SC 13G/A - Evogene Ltd. (0001574565) (Subject)

      2/11/22 12:15:01 PM ET
      $EVGN
      Agricultural Chemicals
      Industrials